219) This is used to collect data on summary COVID-19 vaccination counts among HCP working in a
Dexamethasone is now the standard of care for COVID-19 patients with acute hypoxemic respiratory failure (i
Background Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19)
9% of participants
For patients who are immunocompromised and who were on chronic corticosteroids prior to hospitalization, the optimal dose of dexamethasone for the treatment of COVID-19 is unknown
Continue to monitor glucose 6 hourly and down titrate using the guidance table above DISCHARGE AND FOLLOW-UP › Diabetes precipitated by COVID-19 infection
Dexamethasone IV Injection • Albuterol 2
Clinicians should follow hospital protocols for managing anticoagulation in patients with thrombocytopenia
View dexamethasone information, including dose, uses, side-effects, renal impairment, pregnancy, breast feeding, contra-indications and monitoring requirements
A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19
Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial Trials
It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and
tocilizumab)
Dexamethasone, an inexpensive and widely available steroid, has saved around one million lives worldwide since its discovery as an effective treatment for COVID-19 in a clinical trial in the NHS
Methods: REMED is a prospective, open-label, randomised controlled trial testing the superiority of dexamethasone 20 mg (dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10) vs 6 mg administered once daily intravenously for 10 days in adult patients with moderate or severe
In nonhospitalized patients with COVID-19, the Panel recommends against the use of anticoagulant and antiplatelet therapy (i